When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters was with a 24-year-old patient whose sickle cell disease left them with almost weekly pain episodes.
AI models redefine TIL scoring in breast cancer but face challenges in real-world validation
AI models analyzing tumor-infiltrating lymphocytes show promise in predicting outcomes for triple-negative breast cancer, but external validation reveals critical performance gaps.
November 22, 2024